Cowen and Company assumed coverage on shares of MediWound Ltd. (NASDAQ:MDWD) in a research report released on Thursday morning, Marketbeat reports. The brokerage issued an outperform rating and a $9.00 price objective on the biopharmaceutical company’s stock.

Several other research firms have also recently issued reports on MDWD. SunTrust Banks, Inc. reissued a buy rating on shares of MediWound in a research report on Monday, June 26th. Zacks Investment Research upgraded shares of MediWound from a strong sell rating to a hold rating in a research note on Wednesday, August 2nd. Jefferies Group LLC set a $10.00 target price on shares of MediWound and gave the stock a buy rating in a research report on Friday, August 25th. Oppenheimer Holdings, Inc. reaffirmed a buy rating and set a $10.00 target price on shares of MediWound in a research report on Monday, September 18th. Finally, ValuEngine downgraded shares of MediWound from a sell rating to a strong sell rating in a research note on Friday, September 22nd. Two investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $9.15.

MediWound (MDWD) opened at 5.35 on Thursday. The firm’s 50 day moving average price is $6.30 and its 200-day moving average price is $6.53. The stock’s market cap is $117.45 million. MediWound has a 12-month low of $4.25 and a 12-month high of $8.25.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.01). The company had revenue of $0.69 million during the quarter, compared to the consensus estimate of $0.69 million. MediWound had a negative return on equity of 326.32% and a negative net margin of 752.78%. The company’s revenue for the quarter was up 93.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.34) earnings per share. Equities research analysts anticipate that MediWound will post ($0.76) earnings per share for the current fiscal year.

WARNING: “MediWound Ltd. (MDWD) Research Coverage Started at Cowen and Company” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/02/mediwound-ltd-mdwd-research-coverage-started-at-cowen-and-company.html.

Hedge funds have recently added to or reduced their stakes in the stock. Migdal Insurance & Financial Holdings Ltd. lifted its stake in MediWound by 20.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock worth $13,791,000 after acquiring an additional 342,165 shares during the period. Wells Fargo & Company MN increased its position in MediWound by 23.5% during the 2nd quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock valued at $447,000 after purchasing an additional 12,522 shares during the period. Renaissance Technologies LLC increased its position in MediWound by 1.7% during the 1st quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 1,300 shares during the period. Finally, Wellington Management Group LLP increased its position in MediWound by 11.0% during the 1st quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock valued at $14,241,000 after purchasing an additional 213,745 shares during the period. Hedge funds and other institutional investors own 19.55% of the company’s stock.

About MediWound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Analyst Recommendations for MediWound (NASDAQ:MDWD)

Receive News & Stock Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related stocks with our FREE daily email newsletter.